The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis

Journal of Nuclear Cardiology

Volumn 20, Issue 2, 2013, Pages 297-306

  Mc Ardle, B A ^a   Leung, E ^b   Ohira, H ^a   Cocker, M S ^a   Dekemp, R A ^a   Dasilva, J ^a   Birnie, D ^a   Beanlands, R S ^a   Nery, P B ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Fluorodeoxyglucose (FDG); inflammation; metabolism: PET

Indexed keywords

AMMONIA N 13; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; PREDNISONE; RUBIDIUM 82; STEROID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ATRIOVENTRICULAR BLOCK; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPLETE HEART BLOCK; COMPUTED TOMOGRAPHY SCANNER; DEFIBRILLATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DYSPNEA; ELECTROCARDIOGRAPHY; ENDOCARDIAL BIOPSY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MYOCARDITIS; PACEMAKER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; TREATMENT REFUSAL; WHOLE BODY SCINTISCANNING;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOIDOSIS;

EID: 84879500294     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9668-9     Document Type: Review

References (29)

1. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-72.
2. Iwai K, Takemura T, Kitaichi M, Kawabata Y, Matsui Y. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993;43:377-85.
3. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-63.
4. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circul Arrhythm Electrophysiol 2011;4:303-9.
5. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
6. Hiraga H, Yuwai K, Hiroe M, et al. Guideline for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary diseases. Tokyo: The Japanese Ministry of Health and Welfare; 1993. p 23-4. (in Japanese).
7. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: Applications of imaging in diagnosis and directing treatment. Heart 2011;97:2078-87.
8. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.
9. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11.
10. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.
11. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.
12. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
13. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.
14. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Medicine 2012;53:241-8.
15. Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: Diagnosis and treatment. Curr Opin Cardiol 2012;27:181-9.
16. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.
17. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F]fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232-7.
18. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190:W151-6.
19. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563-8.
20. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286-91.
21. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531-3.
22. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.
23. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
24. Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med 2008;29:493-508. ix.
25. Sadek MYD, Birnie D, Beanlands RS, Nery P. Steroids and the treatment of cardiac sarcoidosis: A systematic review (abstract). Can J Cardiol 2012;28:S337.
26. Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: A call for prospective studies of newer imaging techniques. Eur Respir J 2007;29:418-22.
27. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461-8.
28. Nery P, Keren A, Healey J, Leung E, Beanlands RS, Birnie D. Isolated cardiac sarcoidosis: Establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 2012. doi: 10.1016/j.cjca.2012.09.009.
29. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:537-40.